CVC CAPITAL 13.510 € (-0,22 %)
EMEIS 15.410 € (+0,78 %)
FERMENTALG 0.572 € (-4,03 %)
FDJ UNITED 22.870 € (-0,48 %)
VIRIDIEN 115.500 € (-3,27 %)
AYVENS 11.320 € (-0,70 %)
PULLUP ENTERTAIN 8.770 € (-0,90 %)
OPMOBILITY 15.680 € (+1,23 %)
METAVISIO 0.001 € (+9,09 %)
CEGEDIM 10.960 € (+1,29 %)
EXOSENS 62.900 € (-2,25 %)
FERROVIAL 60.660 € (-0,36 %)
TITAN 2.700 € (-14,01 %)
PLANISWARE 17.950 € (+0,50 %)
CARREFOUR 17.145 € (+0,03 %)
THALES 237.000 € (-1,66 %)
LVMH 484.050 € (+2,12 %)
EUROFINS SCIENT. 60.260 € (+0,43 %)
VEOLIA ENVIRON. 36.460 € (+0,72 %)
GTT 209.600 € (-0,47 %)
DASSAULT AVIATION 305.000 € (-0,91 %)
GALP ENERGIA-NOM 19.010 € (-1,48 %)
AIR LIQUIDE 177.460 € (-1,56 %)
STMICROELECTRONICS 48.715 € (+0,44 %)
ELIS 28.060 € (+1,67 %)
AIRBUS 185.960 € (-1,35 %)
ENGIE 27.280 € (-1,05 %)
SCHNEIDER ELECTRIC 283.850 € (+0,41 %)
EXAIL TECHNOLOGIES 115.000 € (-5,27 %)
ALTEN 62.400 € (+0,89 %)
SAFRAN 299.400 € (+0,91 %)
BONDUELLE 8.160 € (-4,23 %)
PUBLICIS GROUPE SA 81.800 € (+0,15 %)
BOUYGUES 51.320 € (-3,17 %)
74SOFTWARE 37.200 € (+0,54 %)
SOCIETE GENERALE 70.830 € (+1,19 %)
L'OREAL 370.950 € (-0,66 %)
UBISOFT ENTERTAIN 4.855 € (-1,40 %)
TOTALENERGIES 75.260 € (-1,94 %)
ABIVAX 106.800 € (-3,09 %)
PROSUS 42.385 € (+1,21 %)
AXA 41.620 € (-0,43 %)
ASML HOLDING 1 306.000 € (+0,08 %)
SANOFI 73.930 € (-0,95 %)
SOITEC 150.450 € (+2,45 %)
WOLTERS KLUWER 61.540 € (-2,96 %)
COFACE 16.260 € (+0,56 %)
ADOCIA 5.075 € (+5,64 %)
ADYEN 964.300 € (+0,70 %)
RELX 28.760 € (-5,27 %)
UNILEVER 50.510 € (-0,30 %)
AEGON 7.168 € (+0,06 %)
PHARMING GROUP 1.099 € (-21,22 %)
SHELL PLC 36.385 € (-2,06 %)
ABN AMRO BANK N.V. 30.560 € (+1,13 %)
BUREAU VERITAS 26.860 € (+0,22 %)
SMCP 5.255 € (+0,77 %)
BNP PARIBAS ACT.A 93.720 € (+0,33 %)
CSG 16.368 € (-4,03 %)
ESSILORLUXOTTICA 177.600 € (+0,51 %) |
16/04/2026 20:35
EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior yearEQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 766 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million). Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year. Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million). Forecast for 2026 The full results for the first three months of the fiscal year will be published on April 30, 2026.
Drägerwerk AG & Co. KGaA
Investor Relations:
Disclaimer End of Inside Information Changed circumstances / true information: Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 756 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million). Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year. Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million). Forecast for 2026 The full results for the first three months of the fiscal year will be published on April 30, 2026.
Drägerwerk AG & Co. KGaA
Investor Relations:
Disclaimer 16-Apr-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
2310104 16-Apr-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière